0001641172-25-011519.txt : 20250519 0001641172-25-011519.hdr.sgml : 20250519 20250519172312 ACCESSION NUMBER: 0001641172-25-011519 CONFORMED SUBMISSION TYPE: 10-Q/A PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20250331 FILED AS OF DATE: 20250519 DATE AS OF CHANGE: 20250519 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Immix Biopharma, Inc. CENTRAL INDEX KEY: 0001873835 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 454869378 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q/A SEC ACT: 1934 Act SEC FILE NUMBER: 001-41159 FILM NUMBER: 25965168 BUSINESS ADDRESS: STREET 1: 11400 WEST OLYMPIC BLVD. STREET 2: SUITE 200 CITY: LOS ANGELES STATE: CA ZIP: 90064 BUSINESS PHONE: (888) 958-1084 MAIL ADDRESS: STREET 1: 10573 W. PICO BLVD. STREET 2: #58 CITY: LOS ANGELES STATE: CA ZIP: 90064 10-Q/A 1 form10-qa.htm 10-Q/A
true Q1 --12-31 0001873835 0001873835 2025-01-01 2025-03-31 0001873835 2025-05-06 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure iso4217:AUD utr:acre IMMX:Segment

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

FORM 10-Q/A

(Amendment No. 1)

 

(Mark One)

 

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended March 31, 2025

 

OR

 

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from _________to ___________

 

Commission File Number: 001-41159

 

IMMIX BIOPHARMA, INC.

(Exact Name of Registrant as Specified in its Charter)

 

Delaware   45-4869378

(State or other jurisdiction of
incorporation or organization)

 

(I.R.S. Employer

Identification No.)

 

11400 West Olympic Blvd., Suite 200, Los Angeles, CA   90064
(Address of principal executive offices)   (Zip Code)

 

(310) 651-8041

(Registrant’s telephone number, including area code)

 

Not applicable

(Former name, former address and former fiscal year, if changed since last report)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common stock, $0.0001 par value   IMMX   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer   Accelerated filer
         
Non-accelerated filer   Smaller reporting company
         
      Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No

 

Number of shares of common stock outstanding as of May 6, 2025 was 27,877,293.

 

 

 

 

 

 

EXPLANATORY NOTE

 

This Amendment No 1. to the Quarterly Report on Form 10-Q of Immix Biopharma, Inc. (the “Company”) for the quarter ended March 31, 2025 (this “Amendment”) is being filed to amend the original Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, filed by the Company with the Commission on May 8, 2025 (the “Original Report”), to include certifications of Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, which were inadvertently omitted from the Original Report. These certificates are furnished, as Exhibit 32.1 to this Amendment.

 

This Amendment contains only the Cover Page to this Amendment, this Explanatory Note, Item 6, the Signature Page, and the certifications attached to this Amendment as Exhibits 31.1 and 31.2 and Exhibit 32.1. No other changes have been made to the Original Form 10-Q. This Amendment speaks as of the original filing date of the Original Form 10-Q, does not reflect events that may have occurred subsequent to the original filing date, and does not modify or update in any way disclosures made in the Original Form 10-Q.

 

The filing of this Amendment is not an admission that the Original Form 10-Q, when filed, included any untrue statement of a material fact or omitted to state a material fact necessary to make a statement not misleading. Information not affected by this Amendment remains unchanged and reflects the disclosures made at the time of the Original Report. Accordingly, this Amendment should be read in conjunction with the Original Form 10-Q and our other filings with the SEC.

 

 

 

 

PART II — OTHER INFORMATION

 

ITEM 6. EXHIBITS.

 

Exhibit No.   Description
     
31.1*   Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
     
31.2*   Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
     
32.1**   Certifications of Principal Executive Officer and Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
     
101.INS*   Inline XBRL Instance Document
     
101.SCH*   Inline XBRL Taxonomy Extension Schema Document
     
101.CAL*   Inline XBRL Taxonomy Extension Calculation Linkbase Document
     
101.DEF*   Inline XBRL Taxonomy Extension Definition Linkbase Document
     
101.LAB*   Inline XBRL Taxonomy Extension Label Linkbase Document
     
101.PRE*   Inline XBRL Taxonomy Extension Presentation Linkbase Document
     
104*   Cover Page Interactive Data File - the cover page from the Registrant’s Quarterly Report on Form 10-Q/A for the quarter ended March 31, 2025 is formatted in Inline XBRL and included in the Exhibit 101 Inline XBRL Document Set

 

* Filed herewith.
** Furnished herewith.

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

  IMMIX BIOPHARMA, INC.
   
Date: May 19, 2025 By: /s/ Ilya Rachman
    Ilya Rachman
    Chief Executive Officer
    (Principal Executive Officer)
     
Date: May 19, 2025 By: /s/ Gabriel Morris
    Gabriel Morris,
    Chief Financial Officer
    (Principal Financial and Accounting Officer)

 

 

 

EX-31.1 2 ex31-1.htm EX-31.1

 

Exhibit 31.1

 

Certification of Chief Executive Officer of Immix Biopharma, Inc.

Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

 

I, Ilya Rachman, certify that:

 

1. I have reviewed this Quarterly Report on Form 10-Q/A of Immix Biopharma, Inc.; and
   
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report.

 

Date: May 19, 2025 /s/ Ilya Rachman
  Ilya Rachman
 

Chief Executive Officer

(Principal Executive Officer)

 

 

 

EX-31.2 3 ex31-2.htm EX-31.2

 

Exhibit 31.2

 

Certification of Chief Financial Officer of Immix Biopharma, Inc.

Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

 

I, Gabriel Morris, certify that:

 

1. I have reviewed this Quarterly Report on Form 10-Q/A of Immix Biopharma, Inc.; and
   
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report.

 

Date: May 19, 2025 /s/ Gabriel Morris
  Gabriel Morris
 

Chief Financial Officer

(Principal Financial and Accounting Officer)

 

 

 

EX-32.1 4 ex32-1.htm EX-32.1

 

Exhibit 32.1

 

Statement of Chief Executive Officer and Chief Financial Officer

Pursuant to Section 1350 of Title 18 of the United States Code

 

Pursuant to Section 1350 of Title 18 of the United States Code as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned, Ilya Rachman, hereby certifies that based on the undersigned’s knowledge:

 

1. The Quarterly Report on Form 10-Q of Immix Biopharma, Inc. (the “Company”) for the quarter ended March 31, 2025, as originally filed on May 8, 2025 and amended by Quarterly Report on Form 10-Q/A filed on May 19, 2025, fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

2. The information contained in such Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated.

 

Date: May 19, 2025 /s/ Ilya Rachman
  Ilya Rachman
  Chief Executive Officer
  (Principal Executive Officer)

 

Pursuant to Section 1350 of Title 18 of the United States Code as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned, Gabriel Morris, hereby certifies that based on the undersigned’s knowledge:

 

1. The Quarterly Report on Form 10-Q of Immix Biopharma, Inc. (the “Company”) for the quarter ended March 31, 2025, as originally filed on May 8, 2025 and amended by Quarterly Report on Form 10-Q/A filed on May 19, 2025, fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

2. The information contained in such Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated.

 

Date: May 19, 2025 /s/ Gabriel Morris
  Gabriel Morris
  Chief Financial Officer
  (Principal Financial and Accounting Officer)

 

 

 

EX-101.SCH 5 immx-20250331.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 6 immx-20250331_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 7 immx-20250331_pre.xml XBRL PRESENTATION FILE XML 9 R1.htm IDEA: XBRL DOCUMENT v3.25.1
Cover - shares
3 Months Ended
Mar. 31, 2025
May 06, 2025
Cover [Abstract]    
Document Type 10-Q/A  
Amendment Flag true  
Amendment Description This Amendment No 1. to the Quarterly Report on Form 10-Q of Immix Biopharma, Inc. (the “Company”) for the quarter ended March 31, 2025 (this “Amendment”) is being filed to amend the original Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, filed by the Company with the Commission on May 8, 2025 (the “Original Report”), to include certifications of Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, which were inadvertently omitted from the Original Report. These certificates are furnished, as Exhibit 32.1 to this Amendment.This Amendment contains only the Cover Page to this Amendment, this Explanatory Note, Item 6, the Signature Page, and the certifications attached to this Amendment as Exhibits 31.1 and 31.2 and Exhibit 32.1. No other changes have been made to the Original Form 10-Q. This Amendment speaks as of the original filing date of the Original Form 10-Q, does not reflect events that may have occurred subsequent to the original filing date, and does not modify or update in any way disclosures made in the Original Form 10-Q.  The filing of this Amendment is not an admission that the Original Form 10-Q, when filed, included any untrue statement of a material fact or omitted to state a material fact necessary to make a statement not misleading. Information not affected by this Amendment remains unchanged and reflects the disclosures made at the time of the Original Report. Accordingly, this Amendment should be read in conjunction with the Original Form 10-Q and our other filings with the SEC.  
Document Quarterly Report true  
Document Transition Report false  
Document Period End Date Mar. 31, 2025  
Document Fiscal Period Focus Q1  
Document Fiscal Year Focus 2025  
Current Fiscal Year End Date --12-31  
Entity File Number 001-41159  
Entity Registrant Name IMMIX BIOPHARMA, INC.  
Entity Central Index Key 0001873835  
Entity Tax Identification Number 45-4869378  
Entity Incorporation, State or Country Code DE  
Entity Address, Address Line One 11400 West Olympic Blvd.  
Entity Address, Address Line Two Suite 200  
Entity Address, City or Town Los Angeles  
Entity Address, State or Province CA  
Entity Address, Postal Zip Code 90064  
City Area Code (310)  
Local Phone Number 651-8041  
Title of 12(b) Security Common stock, $0.0001 par value  
Trading Symbol IMMX  
Security Exchange Name NASDAQ  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Non-accelerated Filer  
Entity Small Business true  
Entity Emerging Growth Company true  
Elected Not To Use the Extended Transition Period false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   27,877,293
XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ .report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } .report table.authRefData a { display: block; font-weight: bold; } .report table.authRefData p { margin-top: 0px; } .report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } .report table.authRefData .hide a:hover { background-color: #2F4497; } .report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } .report table.authRefData table{ font-size: 1em; } /* Report Styles */ .pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ .report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } .report hr { border: 1px solid #acf; } /* Top labels */ .report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } .report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } .report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } .report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } .report td.pl div.a { width: 200px; } .report td.pl a:hover { background-color: #ffc; } /* Header rows... */ .report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ .report .rc { background-color: #f0f0f0; } /* Even rows... */ .report .re, .report .reu { background-color: #def; } .report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ .report .ro, .report .rou { background-color: white; } .report .rou td { border-bottom: 1px solid black; } .report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ .report .fn { white-space: nowrap; } /* styles for numeric types */ .report .num, .report .nump { text-align: right; white-space: nowrap; } .report .nump { padding-left: 2em; } .report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ .report .text { text-align: left; white-space: normal; } .report .text .big { margin-bottom: 1em; width: 17em; } .report .text .more { display: none; } .report .text .note { font-style: italic; font-weight: bold; } .report .text .small { width: 10em; } .report sup { font-style: italic; } .report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.25.1 html 2 32 1 false 0 0 false 7 false false R1.htm 00000001 - Document - Cover Sheet http://immixbio.com/role/Cover Cover Cover 1 false false All Reports Book All Reports form10-qa.htm immx-20250331.xsd immx-20250331_lab.xml immx-20250331_pre.xml http://xbrl.sec.gov/dei/2024 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "form10-qa.htm": { "nsprefix": "IMMX", "nsuri": "http://immixbio.com/20250331", "dts": { "inline": { "local": [ "form10-qa.htm" ] }, "schema": { "local": [ "immx-20250331.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd" ] }, "labelLink": { "local": [ "immx-20250331_lab.xml" ] }, "presentationLink": { "local": [ "immx-20250331_pre.xml" ] } }, "keyStandard": 32, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 4, "http://xbrl.sec.gov/dei/2024": 4 }, "contextCount": 2, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 7, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2024": 32 }, "report": { "R1": { "role": "http://immixbio.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "From2025-01-01to2025-03-31", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "form10-qa.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2025-01-01to2025-03-31", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "form10-qa.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentDescription", "presentation": [ "http://immixbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": [ "http://immixbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AnnualInformationForm", "presentation": [ "http://immixbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://immixbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": [ "http://immixbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CountryRegion", "presentation": [ "http://immixbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://immixbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentAccountingStandard", "presentation": [ "http://immixbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentAnnualReport", "presentation": [ "http://immixbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://immixbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://immixbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": [ "http://immixbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodStartDate", "presentation": [ "http://immixbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentQuarterlyReport", "presentation": [ "http://immixbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentRegistrationStatement", "presentation": [ "http://immixbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://immixbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentShellCompanyReport", "presentation": [ "http://immixbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": [ "http://immixbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": [ "http://immixbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://immixbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": [ "http://immixbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine2", "presentation": [ "http://immixbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine3", "presentation": [ "http://immixbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": [ "http://immixbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCountry", "presentation": [ "http://immixbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://immixbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://immixbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://immixbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": [ "http://immixbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://immixbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://immixbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://immixbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityExTransitionPeriod", "presentation": [ "http://immixbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": [ "http://immixbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": [ "http://immixbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://immixbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://immixbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityPrimarySicNumber", "presentation": [ "http://immixbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://immixbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": [ "http://immixbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": [ "http://immixbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": [ "http://immixbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://immixbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityVoluntaryFilers", "presentation": [ "http://immixbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://immixbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Extension", "presentation": [ "http://immixbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": [ "http://immixbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "NoTradingSymbolFlag", "presentation": [ "http://immixbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://immixbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://immixbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementTenderOffer", "presentation": [ "http://immixbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": [ "http://immixbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12gTitle", "presentation": [ "http://immixbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": [ "http://immixbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityReportingObligation", "presentation": [ "http://immixbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SolicitingMaterial", "presentation": [ "http://immixbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": [ "http://immixbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "WrittenCommunications", "presentation": [ "http://immixbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14a", "Subsection": "12" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 16 0001641172-25-011519-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001641172-25-011519-xbrl.zip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end XML 17 form10-qa_htm.xml IDEA: XBRL DOCUMENT 0001873835 2025-01-01 2025-03-31 0001873835 2025-05-06 iso4217:USD shares iso4217:USD shares pure iso4217:AUD utr:acre IMMX:Segment true Q1 --12-31 0001873835 10-Q/A true 2025-03-31 2025 false 001-41159 IMMIX BIOPHARMA, INC. DE 45-4869378 11400 West Olympic Blvd. Suite 200 Los Angeles CA 90064 (310) 651-8041 Common stock, $0.0001 par value IMMX NASDAQ Yes Yes Non-accelerated Filer true true false false 27877293 This Amendment No 1. to the Quarterly Report on Form 10-Q of Immix Biopharma, Inc. (the “Company”) for the quarter ended March 31, 2025 (this “Amendment”) is being filed to amend the original Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, filed by the Company with the Commission on May 8, 2025 (the “Original Report”), to include certifications of Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, which were inadvertently omitted from the Original Report. These certificates are furnished, as Exhibit 32.1 to this Amendment.This Amendment contains only the Cover Page to this Amendment, this Explanatory Note, Item 6, the Signature Page, and the certifications attached to this Amendment as Exhibits 31.1 and 31.2 and Exhibit 32.1. No other changes have been made to the Original Form 10-Q. This Amendment speaks as of the original filing date of the Original Form 10-Q, does not reflect events that may have occurred subsequent to the original filing date, and does not modify or update in any way disclosures made in the Original Form 10-Q.  The filing of this Amendment is not an admission that the Original Form 10-Q, when filed, included any untrue statement of a material fact or omitted to state a material fact necessary to make a statement not misleading. Information not affected by this Amendment remains unchanged and reflects the disclosures made at the time of the Original Report. Accordingly, this Amendment should be read in conjunction with the Original Form 10-Q and our other filings with the SEC.